cyclacel.com (BGMS): Debt to Equity

Bio Green Med Solution Inc (BGMS) acts as a biopharmaceutical pioneer, developing agents for the targeted suppression of aggressive neoplasms. Simultaneously, the company implements green manufacturing principles and minimizes harmful emissions within its laboratories. This price trend chart demonstrates a total debt-to-equity ratio of 0.00. The business specializes in cell cycle regulators, reducing potential losses by utilizing outsourcing for clinical trials.

This ratio compares total liabilities to equity, determining the business's reliance on debt financing and its overall financial stability. By analyzing the company's leverage relative to capital, an investor assesses the default risk of Bio Green Med Solution Inc. (BGMS) against the costs of clinical trials for cell cycle inhibitors and the anticipated interest from major oncopharmaceutical behemoths.